Liu C, Bayer A, Cosgrove SE, et al. Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–55. https://doi.org/10.1093/cid/ciq146.

Article  PubMed  Google Scholar 

O’Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist. 2015;8:217–30. https://doi.org/10.2147/IDR.S54125.

Article  PubMed  PubMed Central  Google Scholar 

Thabit AK, Fatani DF, Bamakhrama MS, et al. Antibiotic penetration into bone and joints: an updated review. Int J Infect Dis. 2019;81:128–36. https://doi.org/10.1016/j.ijid.2019.02.005.

Article  CAS  PubMed  Google Scholar 

Shorr AF, Lodise TP, Corey GR, et al. Analysis of the Phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59:864–71. https://doi.org/10.1128/AAC.03688-14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled Phase III studies. Antimicrob Agents Chemother. 2003;47:1824–31. https://doi.org/10.1128/AAC.47.6.1824-1831.2003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsutsumi T, Imai S, Yamada K, et al. Verification of relationship between administration of linezolid and vomiting. Yakugaku Zasshi. 2019;139:1055–61. https://doi.org/10.1248/yakushi.19-00010.

Article  CAS  PubMed  Google Scholar 

Tsutsumi T, Imai S, Kashiwagi H, et al. Investigation of the risk factors of vomiting during linezolid therapy: a retrospective observational study. Eur J Clin Pharmacol. 2022;78:279–86. https://doi.org/10.1007/s00228-021-03221-x.

Article  CAS  PubMed  Google Scholar 

Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47:2775–80. https://doi.org/10.1128/AAC.47.9.2775-2780.2003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zyvox® package insert, U.S Food & Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021130s044,021131s041,021132s043lbl.pdf. Accessed 31 Oct 2023.

Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32:402–12. https://doi.org/10.1086/318486.

Article  CAS  PubMed  Google Scholar 

Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34:1481–90. https://doi.org/10.1086/340353.

Article  CAS  PubMed  Google Scholar 

Nukui Y, Hatakeyama S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68:2128–33. https://doi.org/10.1093/jac/dkt133.

Article  CAS  PubMed  Google Scholar 

Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375:2293–7. https://doi.org/10.1056/NEJMsb1609216.

Article  PubMed  Google Scholar 

United States Food and Drug Administration. Real-world evidence. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence. Accessed 31 Oct 2023.

JMDC website. https://www.jmdc.co.jp/en/. Accessed 31 Oct 2023.

Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77:835–64.

Article  PubMed  Google Scholar 

Chiappini E, Conti C, Galli L, et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010;32:66–88. https://doi.org/10.1016/j.clinthera.2010.01.019.

Article  CAS  PubMed  Google Scholar 

Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42:1578–83. https://doi.org/10.1086/503839.

Article  CAS  PubMed  Google Scholar 

Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011;51:229–36. https://doi.org/10.1177/0091270010366445.

Article  CAS  PubMed  Google Scholar 

Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374:1356–67. https://doi.org/10.1056/NEJMra1515442.

Article  CAS  PubMed  Google Scholar 

Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2020;131:411–48. https://doi.org/10.1213/ANE.0000000000004833.

Article  PubMed  Google Scholar 

Schwartzberg L, Jackson J, Jain G, et al. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. Expert Rev Pharmacoecon Outcomes Res. 2011;11:481–8. https://doi.org/10.1586/erp.11.47.

Article  PubMed  Google Scholar 

Katz, MH. Evaluating Clinical and Public Health Interventions: A Practical Guide to Study Design and Statistics. Cambridge University Press; 2010. [Japanese Edition] ISBN: 978–4–89592–757–4, pp. 105–6

Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424. https://doi.org/10.1080/00273171.2011.568786.

Article  PubMed  PubMed Central  Google Scholar 

Abe S, Chiba K, Cirincione B, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol. 2009;49:1071–8. https://doi.org/10.1177/0091270009337947.

Article  CAS  PubMed  Google Scholar 

Yamana H, Konishi T, Yasunaga H. Validation studies of Japanese administrative health care data: A scoping review. Pharmacoepidemiol Drug Saf. 2023;32:705–17. https://doi.org/10.1002/pds.5636.

Article  PubMed  Google Scholar 

Soriano A, Miró O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med. 2005;353:2305–6. https://doi.org/10.1056/NEJM200511243532123.

Article  CAS  PubMed  Google Scholar 

Ioannou P, Stavroulaki M, Mavrikaki V, et al. A case of severe hyponatremia due to linezolid-induced SIADH. J Clin Pharm Ther. 2018;43:434–6. https://doi.org/10.1111/jcpt.12681.

Article  CAS  PubMed  Google Scholar 

Dai Y, Wang Y, Zeng Y, et al. Linezolid and the risk of lactic acidosis: data mining and analysis of the FDA Adverse Event Reporting System. J Clin Pharm Ther. 2020;45:1422–6. https://doi.org/10.1111/jcpt.13245.

Article  CAS  PubMed  Google Scholar